Regular characterization of induced pluripotent stem cells (iPSCs), to ascertain maintenance of their pluripotent state, is an important step before these cells are used for other applications. Here we describe a method for the small-scale propagation of human iPSCs specifically designed to enable their easy and routine characterization via immunocytochemistry.
There is great interest in utilizing human induced pluripotent stem cells (hiPSCs) for disease modeling and cell therapeutics due to their patient specificity and characteristic stemness. However, the pluripotency of iPSCs, which is essential to their functionality, must be confirmed before these cells can be used in such applications. While a rigorous characterization of iPSCs, through different cellular and functional assays is necessary to establish their pluripotency, routine assessment of pluripotency maintenance can be achieved more simply and effectively through immunocytochemical techniques. Here, we present a systematic protocol for culturing hiPSCs, in a scaled-down manner, to particularly facilitate the verification of their pluripotent state using immunocytochemistry. More specifically, this methodology encompasses an efficient and cost-effective means of growing iPSCs in serum-free conditions and plating them on small chamber slides or glass coverslips ideal for immunocytochemistry.
Reprogramming human adult somatic cells into induced pluripotent stem cells (iPSCs) provides a way to obtain a potentially unlimited supply of patient-specific cells to study disease1,2. Recapitulating a disease phenotype in vitro would make it plausible to examine cellular and molecular mechanisms associated with disease, and enhance drug discovery and personalized medicine3. In addition, human iPSCs (hiPSCs) offer the possibility of deriving specific cell types which can be used as a unique resource to replace dead or dysfunctional cells and restore function in the context of several disorders4,5.
An important prerequisite to using iPSCs in the above applications is ensuring that their pluripotent and undifferentiated state is maintained during expansion in culture. Typically, techniques such as flow cytometry, western blotting, polymerase chain reaction and functional assays, which require large quantities of cells and specialized equipment, are used for the detailed analysis of iPSC pluripotency6,7,8,9,10. However, routine assessment of the iPSCs' undifferentiated state might effectively be achieved through the limited propagation of these cells specifically for immunocytochemistry (ICC), thus involving reduced time and resources.
Recent advances allow for the growth of iPSCs in defined serum-free conditions, which is a significant improvement over conventional culture systems that require murine fibroblast feeder layers and serum containing media. However, the current literature does not include clear stepwise protocols that describe how to transition iPSCs from feeder layer to feeder-free systems.
In this context, the present protocol systematically details how hiPSCs grown on irradiated mouse embryonic fibroblast (iMEF) feeder layers can be (1) adapted to propagate in serum-free medium, and (2) cultured on a small-scale to specifically support robust immunocytochemical analysis. Overall, this methodology represents a timely and cost-effective procedure for propagating human iPSCs in serum-free conditions for confirming their pluripotency on a routine basis using immunocytochemistry.
hiPSCs were derived from human dermal fibroblasts isolated from 4 mm skin punch biopsies and reprogrammed in house via Sendai virus-mediated reprogramming11. The University of Arizona Institutional Review Board approved all procedures for subject recruitment and biopsy collection.
1. Preparation of Extracellular Matrix Coated Surface for iPSC Culture
2. Transfer of hiPSCs Grown on iMEF Feeder Cells onto Extracellular Matrix for Propagation
3. Small-scale Passaging of hiPSCs on Matrix-coated Plates
NOTE: Generally, after the initial transfer of the hiPSCs to matrix coated plates, the cells should be passaged once more in a similar manner to ensure all iMEFs have been eliminated and cells have adapted to feeder-free conditions.
4. Preparation of Chamber Slides and Coverslips for Seeding of hiPSCs for Immunocytochemistry
NOTE: The following protocol utilizes 4-well plastic chamber slides and 12 mm glass coverslips with appropriate volumes of media in the multi-wells to support cost-effective immunocytochemistry. However, media volumes can be increased if the use of larger well and coverslip sizes is desired.
5. Preparation of iPSCs for Immunocytochemistry
6. Immunostaining of hiPSCs with Pluripotency Markers
NOTE: Immunostain hiPSCs with standard pluripotency antibodies. As an example, here cells are double-stained with antibodies targeting one 1 surface and 1 intracellular antigen in a sequential manner as follows: Anti-Stage-Specific Embryonic Antigen-4 (SSEA4) with anti-Octamer-binding protein 4 (OCT-4) and anti-Tra-1-60 with anti-SRY related HMG BOX gene 2 (SOX2) (Please see the Materials Table for antibody details).
7. Preparation for Viewing
This protocol provides a step-wise description of how human iPSCs can be transferred from feeder layer to feeder-free conditions, and subsequently propagated in a limited manner to specifically enable cost-effective immunocytochemistry for confirming pluripotency maintenance. Figure 1 shows a schematic representation of this protocol. Figure 2A shows hiPSC colonies growing on iMEFs in 6-well plates. These colonies exhibit typical morphology with defined borders and dense phase bright centers. As shown in Figure 2B, after the transfer of iPSCs to feeder-free conditions in 12-well plates, colony morphology appears somewhat chaotic with less distinct edges. Also, some iMEFs may remain in the culture at this stage. Figure 2C shows that after an additional passage in the feeder-free system, iPSC colonies display a classic monolayer morphology with a high nucleus to cytoplasm ratio. At this stage, it is seen that iMEFs have been virtually eliminated from the culture.
Colonies growing under feeder-free conditions are mechanically picked and plated onto small multi-well chamber slides or glass coverslips, and probed for specific pluripotency antigens via immunocytochemistry. Figure 3 shows representative colonies that are immunopositive for SSEA4 or Tra-1-60 (3B, 3F, surface pluripotency antigens) and Oct-4 or Sox2 (3 A, 3E, intracellular pluripotency antigens).
Figure 1: Schematic Representation of the Protocol. Overall schema of the described method used to transition human iPSCs from iMEF feeders to feeder-free culture and subsequent probing of cells with pluripotency markers. iMEF: irradiated Mouse Embryonic Fibroblast; iPSC: Induced Pluripotent Stem Cell. Please click here to view a larger version of this figure.
Figure 2. Representative Images of iPSC Colonies Transitioning from iMEF Feeders to Feeder-free Culture Conditions. A) Dense iPSC colony (white arrow) grown on iMEF feeder cells (black arrow). B) After the initial passage on to a matrix-coated 12-well plate in serum-free medium, a few iMEFs may still be observed in culture (black arrow). C) Typical morphology of a monolayer iPSC colony grown feeder-free. No iMEFs remain in culture at this stage. Scale Bar (A-C) = 100 µm. Please click here to view a larger version of this figure.
Figure 3. Immunocytochemical Characterization of Human iPSCs Plated in Small Well Plates. Representative immunofluorescence images of iPSCs, obtained via a confocal microscope, showing the positive expression of pluripotency markers A) Oct-4 (red) and B) SSEA4 (green) with C) the nuclear stain DAPI (blue), and E) Sox2 (red) and F) Tra-1-60 (green) with G) DAPI (blue). D and H show the overlay images relating to A-C and E-G. Scale bar (A-H) = 100 µm. Please click here to view a larger version of this figure.
hiPSC Media for maintenance on Feeders | ||
Component | Stock Concentration | Final Concentration |
DMEM-F12/HEPES | 100% | 80% |
Knockout Serum Replacement | 100% | 20% |
L-Glutamine | 200 mM | 1 mM |
MEM-NEAA | 10 mM | 0.1 mM |
2-mercaptoethanol | 55 mM | 0.1 mM |
Recombinant Human FGF-Basic | 10 µg/mL | 10 ng/mL |
Y-27632 ROCK Inhibitor | 10 µM | |
Matrigel coating for Feeder-Free cultures | ||
Component | Amount | |
Matrigel hESC-qualified Matrix | Dilution Factor 269 µL | |
DMEM-F12/HEPES | 25 mL | |
Note: Dilution Factor is lot dependent and must be ascertained from certificate of analysis | ||
mTeSR1 complete media for Feeder-Free cultures | ||
Component | Amount | |
mTeSR1 Basal Medium | 400 mL | |
mTeSR1 5x Supplement | 100 mL | |
Note: Once mixed, mTeSR1 complete media may be frozen in aliquots and used until component expiration date | ||
Note: mTeSR1 complete media must be warmed at room temperature only. Do not place in water bath |
Table 1: iPSC Culture Media Recipes and Plate Coatings.
4% Paraformaldehyde fixative | |
Component | Amount |
0.1 M PO4 Buffer | 2 L |
Paraformaldehyde, prill | 80 g |
ICC Blocking Solution without Triton-X-100 | |
Component | Amount |
1x Phosphate Buffered Saline | 49 mL |
Normal Goat Serum | 1 mL |
Bovine Serum Albumin | 0.5 g |
ICC Blocking Solution with Triton-X-100 | |
Component | Amount |
1x Phosphate Buffered Saline | 49 mL |
Normal Goat Serum | 1 mL |
Bovine Serum Albumin | 0.5 g |
Triton-X-100 | 200 µL |
Table 2: Fixative and Immunocytochemistry Recipes.
The systematic protocol presented here offers a timesaving and cost-effective method, in the form of a scaled-down culture technique, specifically designed to support effective pluripotency analysis via immunocytochemistry.
The main advantages of the described methodology are as follows. Traditionally more than 3 to 4 passages are needed to transition iPSCs from feeder layers to feeder-free culture conditions in order to eliminate residual iMEFs remaining after the use of bulk dissociation techniques and for typical monolayer morphology to appear12,13. In contrast, the method presented here involves a shortened timeline, which allows for the relatively quick transfer of iPSCs to serum-free conditions via the manual picking of iPSC colonies. The iPSCs are grown in limited amounts in small chamber slides or coverslips conducive for immunocytochemistry. In fact, the volume of culture medium needed per well is just 0.5 mL and the volume of diluted antibody solution required for a single coverslip is as nominal as 40 µL or 300 µL per chamber well, when using this protocol.
We find that the addition of equal parts iMEF conditioned media to the mTeSR1 during the initial passage (Step 2.5) is an important step that aids in the survival and maintenance of the iPSC's pluripotent morphology. In addition, if cell adherence is not optimal after passaging (Steps 2.2, 3.3 and 4.3), troubleshooting can be performed by further optimizing the dissociation times used.
Finally, a limitation of the presented small-scale method, when compared to other techniques such as flow cytometry also used to verify pluripotency, is that it does not allow for the continued propagation of analyzed cells for downstream applications. The usefulness of our method arises from its specific design which supports the cost-effective and efficient culture of the hiPSCs for confirming pluripotency via routine immunocytochemistry.
The authors have nothing to disclose.
Funding Sources: The University of Arizona, The Jim Himelic Foundation, and the Arizona Center for the Biology of Complex Diseases.
DMEM-F12/HEPES | Life Technologies | 11330032 | |
Knockout Serum Replacement | Life Technologies | 10828028 | |
L-Glutamine | Life Technologies | 25030081 | |
MEM-NEAA | Life Technologies | 11140050 | |
2-mercaptoethanol | Life Technologies | 21985023 | |
Recombinant Human FGF-Basic | Cell Sciences | CRF001B | |
Y-27632 ROCK Inhibitor | R&D | 1254 | |
Collagenase Type IV | Life Technologies | 17104019 | |
Matrigel hESC-qualified Matrix | Corning | 354277 | |
mTeSR1 Basal Medium | StemCell Technologies | 05850 | |
mTeSR1 5X Supplement | StemCell Technologies | 05850 | |
Gentle Cell Dissociation Buffer | StemCell Technologies | 07174 | |
0.1M PO4 Buffer | In-House | n/a | |
Paraformaldeyde, prill | Electron Microscopy Sciences | 19202 | |
1X Phoshate Buffered Saline | n/a | n/a | |
Normal Goat Serum | Life Technologies | 16210072 | |
Bovine Serum Albumin | Sigma-Aldrich | A2153 | |
Triton-X-100 | Sigma-Aldrich | X100 | |
Oct-4A (C30A3) Rabbit mAb, Sox2 (D6D9) Rabbit mAb, SSEA4 (MC813) Mouse mAb, TRA-1-60(S) (TRA-1-60(S)) Mouse mAb |
Cell Signaling Cell Signaling Cell Signaling Cell Signaling |
2840 3579 4755 4746 |
Alternatively, a combination of 6 pluripotency primary antibodies can be purchased together as a kit in Catalog #9656 |
Goat anti-Ms IgM Alexa Fluor 488 | Life Technologies | A21042 | |
Goat anti-Ms IgG3 Alexa Fluor 488 | Life Technologies | A21151 | |
Goat anti-Rb IgG Alexa Fluor 594 | Life Technologies | A11037 | |
Multiwell Cell Culture Plates | Fisher Scientific | 0720080/0720081 | Available in 6, 12, 24, 48, 96 well sizes |
Chamber Slides | Fisher Scientific | 12 565 21 | Available in Glass or Permanox Plastic in 1, 2, 4, 8, 16 well sizes |
Coverglass for growth | Fisher Scientific | 12 545 82 | Available in 12, 15, 18, 22 and 25mm sizes |